false Q2 --03-31 2026 0001672571 0001672571 2025-04-01 2025-09-30 0001672571 2025-11-12 0001672571 2025-09-30 0001672571 2025-03-31 0001672571 us-gaap:RelatedPartyMember 2025-09-30 0001672571 us-gaap:RelatedPartyMember 2025-03-31 0001672571 us-gaap:CommonClassAMember 2025-09-30 0001672571 us-gaap:CommonClassAMember 2025-03-31 0001672571 us-gaap:CommonClassBMember 2025-09-30 0001672571 us-gaap:CommonClassBMember 2025-03-31 0001672571 us-gaap:CommonClassCMember 2025-09-30 0001672571 us-gaap:CommonClassCMember 2025-03-31 0001672571 AAQL:CommonClassDMember 2025-09-30 0001672571 AAQL:CommonClassDMember 2025-03-31 0001672571 AAQL:CommonClassEMember 2025-09-30 0001672571 AAQL:CommonClassEMember 2025-03-31 0001672571 2025-07-01 2025-09-30 0001672571 2024-07-01 2024-09-30 0001672571 2024-04-01 2024-09-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-03-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001672571 us-gaap:RetainedEarningsMember 2024-03-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001672571 us-gaap:ParentMember 2024-03-31 0001672571 2024-03-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-06-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001672571 us-gaap:RetainedEarningsMember 2024-06-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001672571 us-gaap:ParentMember 2024-06-30 0001672571 2024-06-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-03-31 0001672571 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001672571 us-gaap:RetainedEarningsMember 2025-03-31 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001672571 us-gaap:ParentMember 2025-03-31 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-06-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001672571 us-gaap:RetainedEarningsMember 2025-06-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001672571 us-gaap:ParentMember 2025-06-30 0001672571 2025-06-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-04-01 2024-06-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001672571 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001672571 us-gaap:ParentMember 2024-04-01 2024-06-30 0001672571 2024-04-01 2024-06-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-07-01 2024-09-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001672571 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001672571 us-gaap:ParentMember 2024-07-01 2024-09-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-04-01 2025-06-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001672571 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001672571 us-gaap:ParentMember 2025-04-01 2025-06-30 0001672571 2025-04-01 2025-06-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-07-01 2025-09-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001672571 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001672571 us-gaap:ParentMember 2025-07-01 2025-09-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2024-09-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001672571 us-gaap:RetainedEarningsMember 2024-09-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001672571 us-gaap:ParentMember 2024-09-30 0001672571 2024-09-30 0001672571 us-gaap:CommonStockMember us-gaap:CommonClassAMember 2025-09-30 0001672571 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001672571 us-gaap:RetainedEarningsMember 2025-09-30 0001672571 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001672571 us-gaap:ParentMember 2025-09-30 0001672571 AAQL:StockPurchaseAgreementMember AAQL:Dazhong368IncMember 2019-06-29 2019-07-01 0001672571 AAQL:Dazhong368IncMember AAQL:StockPurchaseAgreementMember 2019-07-01 0001672571 AAQL:MRBarryWanMember AAQL:StockPurchaseAgreementMember 2023-04-09 2023-04-10 0001672571 AAQL:MRBarryWanMember AAQL:StockPurchaseAgreementMember 2023-04-10 0001672571 AAQL:PeriodEndRMBMember 2025-09-30 0001672571 AAQL:PeriodEndPeriodAverageRMBMember 2025-09-30 0001672571 AAQL:PeriodEndRMBMember 2025-03-31 0001672571 AAQL:PeriodEndPeriodAverageRMBMember 2025-03-31 0001672571 AAQL:PeriodEndRMBMember 2024-09-30 0001672571 AAQL:PeriodEndPeriodAverageRMBMember 2024-09-30 0001672571 us-gaap:LeaseholdImprovementsMember 2025-09-30 0001672571 us-gaap:OfficeEquipmentMember 2025-09-30 0001672571 2025-01-01 2025-09-30 0001672571 us-gaap:LeaseholdImprovementsMember 2025-03-31 0001672571 us-gaap:OfficeEquipmentMember 2025-03-31 0001672571 us-gaap:PatentsMember 2025-09-30 0001672571 us-gaap:PatentsMember 2025-03-31 0001672571 AAQL:PromissoryNoteAgreementMember AAQL:ExistingLoanMember 2024-12-31 0001672571 AAQL:PromissoryNoteAgreementMember AAQL:ExistingOfMaturityLoanMember 2024-12-31 0001672571 us-gaap:NonrelatedPartyMember 2024-12-31 2024-12-31 0001672571 us-gaap:NonrelatedPartyMember 2025-03-24 0001672571 us-gaap:NonrelatedPartyMember 2025-03-24 2025-03-24 0001672571 AAQL:MRBarryWanMember 2025-03-31 0001672571 AAQL:MrWanMember 2025-03-31 0001672571 us-gaap:NonrelatedPartyMember 2025-09-30 0001672571 us-gaap:NonrelatedPartyMember 2025-03-31 0001672571 AAQL:MrWanMember 2025-09-30 0001672571 AAQL:NewLiteMember 2025-09-30 0001672571 AAQL:NewLiteMember 2025-03-31 0001672571 us-gaap:RelatedPartyMember 2025-09-30 0001672571 us-gaap:RelatedPartyMember 2025-03-31 0001672571 AAQL:MrWanMember 2024-12-31 0001672571 AAQL:MrWanMember 2024-12-31 2024-12-31 0001672571 us-gaap:RelatedPartyMember AAQL:MrWanSpouseMember 2025-09-30 0001672571 us-gaap:RelatedPartyMember AAQL:MrWanSpouseMember 2025-03-31 0001672571 AAQL:MrWanSpouseMember 2024-12-31 0001672571 AAQL:MrWanSpouseMember 2024-12-31 2024-12-31 0001672571 AAQL:NewLivingMember 2024-12-31 0001672571 AAQL:NewLivingMember 2024-12-31 2024-12-31 0001672571 2008-01-01 2008-01-01 0001672571 country:CN 2025-04-01 2025-09-30 0001672571 country:US 2025-04-01 2025-09-30 0001672571 country:US 2024-04-01 2024-09-30 0001672571 country:HK 2025-04-01 2025-09-30 0001672571 country:HK 2024-04-01 2024-09-30 0001672571 country:CN 2024-04-01 2024-09-30 0001672571 2023-03-28 0001672571 srt:PresidentMember 2024-03-31 0001672571 2024-06-05 0001672571 2024-06-06 0001672571 us-gaap:CommonClassAMember 2024-06-06 0001672571 us-gaap:CommonClassBMember 2024-06-06 0001672571 us-gaap:CommonClassCMember 2024-06-06 0001672571 AAQL:CommonClassDMember 2024-06-06 0001672571 AAQL:CommonClassEMember 2024-06-06 0001672571 AAQL:SalesOfGoodsMember 2025-04-01 2025-09-30 0001672571 AAQL:SalesOfGoodsMember 2024-04-01 2024-09-30 0001672571 us-gaap:TechnologyServiceMember 2025-04-01 2025-09-30 0001672571 us-gaap:TechnologyServiceMember 2024-04-01 2024-09-30 0001672571 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember AAQL:SingleCustomerMember 2025-04-01 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:CNY AAQL:Segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to ______

Commission File Number 000-56157

Antiaging Quantum Living Inc.

(Exact name of registrant as specified in its charter)

New York		47-2643986
(State or Other Jurisdiction		(I.R.S. Employer
of Incorporation or Organization)		Identification No.)

135-27 38th Ave #388

Flushing, NY 11354

(Address of Principal Executive Offices) (Zip Code)

+1 929-990-3255

(Registrant’s telephone number, including area code)

N/A(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Not Applicable		Not Applicable		Not Applicable

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 12, 2025, the registrant had 29,995,000 shares of Class A common stock outstanding.

TABLE OF CONTENTS

		PAGE

	Note about Forward-Looking Statements	3

	PART I - FINANCIAL INFORMATION
Item 1	Financial Statements	4
	Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and March 31, 2025 (audited)	5
	Condensed Consolidated Statements of Income and Comprehensive Income for the three months ended September 30, 2025 and 2024 (unaudited)	6
	Condensed Consolidated Statements of Changes in Shareholders’ Deficit for the six months ended September 30, 2025 and 2024 (unaudited)	7
	Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2025 and 2024 (unaudited)	8
	Notes to Unaudited Condensed Consolidated Financial Statements	9
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operation	23
Item 3	Quantitative and Qualitative Disclosures About Market Risk	26
Item 4	Controls and Procedures	26

	PART II - OTHER INFORMATION

Item 1	Legal Proceedings	27
Item 1A	Risk Factors	27
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 3	Defaults Upon Senior Securities	27
Item 4	Mine Safety Disclosures	27
Item 5	Other Information	27
Item 6	Exhibits	28

SIGNATURES		29

NOTE ABOUT FORWARD-LOOKING STATEMENTS

Except for historical information, this quarterly report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this quarterly report on Form 10-Q other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this quarterly report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

Unless expressly indicated or the context requires otherwise, the terms “Antiaging,” “company,” “we,” “us,” and “our” in this document refer to Antiaging Quantum Living Inc, a New York corporation.

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

INDEX TO FINANCIAL STATEMENTS

Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and March 31, 2025 (audited)	5

Condensed Consolidated Statements of Income and Comprehensive Income for the six months ended September 30, 2025 and 2024 (unaudited)	6

Condensed Consolidated Statements of Changes in Shareholders’ Deficit for the six months ended September 30, 2025 and 2024 (unaudited)	7

Condensed Consolidated Statements of Cash Flows for the six months ended September 30, 2025 and 2024 (unaudited)	8

Notes to Unaudited Condensed Consolidated Financial Statements	9-22

ANTIAGING QUANTUM LIVING INC.

Condensed Consolidated Balance Sheets

As of September 30, 2025 and March 31, 2025

	September 30,			March 31,
	2025			2025
	(Unaudited)			(Audited)
ASSETS
Current Assets
Cash and cash equivalents	$	455,446		$	370,549
Accounts receivable, net		467,804			85,788
Inventory, net		72,250			-
Advances to suppliers		14,126			132,123
Other receivables and current assets		212,551			222,055
Total Current Assets		1,222,177			810,515
Non-Current Assets
Property and equipment, net		204,377			120,769
Intangible assets, net		13,110			13,551
Operating lease right of use asset, net		463,787			644,515
Total Non-Current Assets		681,274			778,835
Total Assets		1,903,451			1,589,350

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current Liabilities
Accounts payable and accrued expenses		173,630			50,244
Other payables		26,675			49,097
Due to related parties		860,000			520,000
Taxes payable		15,328			3,960
Advances from customers		74,476			8,475
Operating lease liabilities - current portion		48,789			46,050
Total Current Liabilities		1,198,898			677,826
Non-Current Liabilities
Operating lease liabilities - non-current		341,920			366,740
Long term notes and loans payable-related party		1,698,330			1,674,801
Total Non-Current Liabilities		2,040,250			2,041,541
Total Liabilities		3,239,148			2,719,367

Commitments and Contingencies		-			-

Shareholders’ Equity
Class A Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; 29,995,000 shares issued and outstanding at September 30, 2025 and March 31, 2025		29,995			29,995
Class B Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at September 30, 2025 and March 31, 2025		-			-
Class C Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at September 30, 2025 and March 31, 2025		-			-
Class D Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at September 30, 2025 and March 31, 2025		-			-
Class E Common stock, par value $0.00001 per share; 1,200,000,000 shares authorized; no shares issued and outstanding at September 30, 2025 and March 31, 2025		-			-
Common stock, value		-			-
Additional paid-in capital		243,530			243,530
Accumulated deficit		(1,604,682	)		(1,409,712	)
Accumulated other comprehensive (loss) income		(4,540	)		6,170
Total Shareholders’ Deficit		(1,335,697	)		(1,130,017	)
Total Liabilities and Shareholders’ Deficit	$	1,903,451		$	1,589,350

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ANTIAGING QUANTUM LIVING INC.

Condensed Consolidated Statements of Operations and Comprehensive Income

For the Three and Six months ended September 30, 2025 and 2024

Unaudited


	Three months Ended						Six months ended
	September 30,			September 30,			September 30,			September 30,
	2025			2024			2025			2024
Revenues, net	$	390,164		$	173,174		$	681,602		$	375,243
Cost of revenues		65,691			14,373			122,397			14,538
Gross profit		324,473			158,801			559,205			360,705

Operating expenses:
Selling and marketing expenses		30,643			100,273			43,255			231,206
General and administrative expenses		345,052			256,296			705,375			541,200
Total operating expenses		375,695			356,569			748,630			772,406

Loss from operations		(51,222	)		(197,768	)		(189,425	)		(411,701	)

Other income :
Interest income		12			22			33			47
Other income		57			-			10,867			-
Total other income		69			22			10,900			47

Loss before income tax		(51,153	)		(197,746	)		(178,525	)		(411,654	)

Income tax expense		10,445			-			16,445			-
Net loss	$	(61,598	)	$	(197,746	)	$	(194,970	)	$	(411,654	)

Weighted average shares outstanding
Basic and diluted		29,995,000			29,950,000			29,995,000			29,950,000

Loss per share
Basic and diluted	$	(0.0021	)	$	(0.0066	)	$	(0.0065	)	$	(0.0137	)

Comprehensive loss:
Net loss	$	(61,598	)	$	(197,746	)	$	(194,970	)	$	(411,654	)
Other comprehensive loss:
Foreign currency translation adjustment		(2,773	)		(19,151	)		(10,710	)		(16,876	)
Total comprehensive loss	$	(64,371	)	$	(216,897	)	$	(205,680	)	$	(428,530	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ANTIAGING QUANTUM LIVING INC.

Condensed Consolidated Statements of Changes in Shareholders’ Deficit

For the Six months ended September 30, 2025 and 2024

Unaudited


										Accumulated			Equity
	Class A Common stock				Additional					other			attributable
	Number of				Paid-in		Accumulated			Comprehensive			to
	Shares		Amount		Capital		Deficit			Income/(Loss)			Owners			Total
Balance at March 31, 2024		29,995,000	$	29,995	$	243,530	$	(689,303	)	$	2,608		$	(413,170	)	$	(413,170	)
Net loss		-		-		-		(213,908	)		-			(213,908	)		(213,908	)
Foreign currency translation adjustment		-		-		-		-			2,275			2,275			2,275
Balance at June 30, 2024		29,995,000		29,995		243,530		(903,211	)		4,883			(624,803	)		(624,803	)
Net loss		-		-		-		(197,746	)		-			(197,746	)		(197,746	)
Foreign currency translation adjustment		-		-		-		-			(19,151	)		(19,151	)		(19,151	)
Balance at September 30, 2024		29,995,000		29,995		243,530		(1,100,957	)		(14,268	)		(841,700	)		(841,700	)

Balance at March 31, 2025		29,995,000		29,995		243,530		(1,409,712	)		6,170			(1,130,017	)		(1,130,017	)
Net loss		-		-		-		(133,372	)		-			(133,372	)		(133,372	)
Foreign currency translation adjustment		-		-		-		-			(7,937	)		(7,937	)		(7,937	)
Balance at June 30, 2025		29,995,000		29,995		243,530		(1,543,084	)		(1,767	)		(1,271,326	)		(1,271,326	)
Balance		29,995,000		29,995		243,530		(1,543,084	)		(1,767	)		(1,271,326	)		(1,271,326	)
Net loss		-		-		-		(61,598	)		-			(61,598	)		(61,598	)
Foreign currency translation adjustment		-		-		-		-			(2,773	)		(2,773	)		(2,773	)
Balance at September 30, 2025		29,995,000		29,995		243,530		(1,604,682	)		(4,540	)		(1,335,697	)		(1,335,697	)
Balance		29,995,000		29,995		243,530		(1,604,682	)		(4,540	)		(1,335,697	)		(1,335,697	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ANTIAGING QUANTUM LIVING INC.

Condensed Consolidated Statements of Cash Flows

For the Six months ended September 30, 2025 and 2024

(In U.S. dollar except for share and per share data)

Unaudited


	Six months ended
	September 30,			September 30,
	2025			2024
Cash flows from operating activities
Net loss	$	(194,970	)	$	(411,654	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense		79,784			71,921
Amortization of operating lease ROU assets		197,511			150,385
Impairment loss on property and equipment’		3,955			-
Changes in assets and liabilities
Increase in accounts receivable		(376,353	)		(26,738	)
Increase in inventories		(72,250	)		-
Decrease (increase) in advances to suppliers		117,997			(12,384	)
Increase in due from relates parties		-			(429	)
Decrease (increase) in other receivables and current assets		11,789			(32,050	)
Increase in customer advances		66,001			4,130
Increase in accounts payable and accrued expenses		125,519			6,883
(Decrease) increase in other payables		(25,980	)		19,207
Increase in taxes payable		11,184			-
(Decrease) increase in operating lease liabilities		(36,000	)		7,571
Net cash used in operating activities		(91,813	)		(223,158	)

Cash flows from investing activities
Purchase of fixed assets		(165,341	)		(44,820	)
Net cash used in investing activities		(165,341	)		(44,820	)

Cash flows from financing activities
Proceeds from related party payables		340,000			138,745
Net cash provided by financing activities		340,000			138,745

Net increase (decrease) of cash and cash equivalents		82,846			(129,233	)
Effect of foreign currency translation on cash and cash equivalents		2,051			84
Cash and cash equivalents – beginning		370,549			166,552
Cash and cash equivalents – ending	$	455,446		$	37,403

Supplementary cash flow information:
Interest paid	$	-		$	-
Income taxes paid	$	10,388		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

ANTIAGING QUANTUM LIVING INC (FKA. ACHISON INC)

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES

Antiaging Quantum Living Inc. (FKA: Achison Inc.) (the “Company”, “us”, “we” or “our”) was incorporated under the laws of the State of New York on December 29, 2014.

On July 1, 2019, Lansdale Inc, the principal stockholder of the Company (“Seller”) an entity controlled by the Company’s former President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the “Agreement”) with Dazhong 368 Inc, (the “Buyer”), pursuant to which, a total of 9,000,000 shares of Class A common stock of the Company were transferred to the Buyer, representing approximately 90% of the Company’s issued and outstanding shares of Class A common stock, resulting in a change of the control of the Company. Mr. Dingshan Zhang was appointed as the President and CEO of the Company at the same date.

On April 10, 2023, Mr. Barry Wan acquired control of 29,215,000 restricted shares of common stock (the “Purchased Shares”) of the Company, representing approximately 97% of the Company’s total issued and outstanding common stock (the “Common Stock”) from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company’s then President, Chief Executive Officer and sole director, Dingshan Zhang (the former President) pursuant to the terms of a Stock Purchase Agreement by and among the parties thereto (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase Agreement (“SPA”), Mr. Wan paid an aggregate purchase price of four hundred thousand dollars ($400,000.00) to Mr. Zhang in exchange for the Purchased Shares. The foregoing transaction resulted in a change of control of the Company, with Mr. Wan acquiring 97% of the Company’s outstanding Common Stock held through New Lite Ventures LLC, a New York LLC. Both before and after the transactions, the Company had 29,995,000 shares of its common stock outstanding.

In connection with the transaction, on April 10, 2023, Mr. Dingshan Zhang resigned from all positions he held with the Company. On April 10, 2023, Ms. Jing Wan was appointed by our majority shareholder as our Chief Executive Officer, Chief Financial Officer, President and Director. On June 16, 2023, Mr. Barry Wan consented to act as the new CEO and CFO after Ms. Jing Wan resigned. The Company was renamed as Antiaging Quantum Living Inc on June 14, 2023 by the new management. The Company is an investment holding company; its primary business operations are conducted through its subsidiaries as described below.

AAQL Inc. (“BVI Holding”) was incorporated under the Laws of the British Virgin Islands to function as a holding company responsible for managing all business operations outside of the United States.

AAQL HK Limited (“Hong Kong Holding”) was incorporated under the Laws of Hong Kong as a wholly-owned subsidiary of the BVI Holding. Hong Kong Holding’s primary role is to act as a holding company overseeing business activities exclusively within the Asia-Pacific markets.

Antiaging Doctor Hangzhou Holding LTD (“Dao Ling Doctor Hangzhou”) was incorporated as a wholly-owned subsidiary of Hong Kong Holding on November 13, 2023 under the laws of the People’s Republic of China, with its principal place of business situated in Xiaoshan District, Hangzhou, Zhejiang Province.

Dao Ling Doctor (Zhejiang) Health Management Limited (“Dao Ling Doctor Zhejiang”) was incorporated as a wholly-owned subsidiary of Dao Ling Doctor Hangzhou on November 30, 2023 under the laws of the People’s Republic of China, with its principal place of business situated in Hangzhou, Zhejiang Province.

Dao Ling Doctor (Huzhou) Health Management Limited (“Dao Ling Doctor Huzhou”) was incorporated as a wholly-owned subsidiary of Dao Ling Doctor Hangzhou on December 6, 2023 under the laws of the People’s Republic of China, with its principal place of business situated in Huzhou, Zhejiang Province.

Anti-Aging Care LLC (“Anti-Aging Care”) was incorporated as a wholly-owned subsidiary of Antiaging Quantum Living Inc. on October 21, 2024 under the laws of New York.

The subsidiaries’ business includes e-commerce platform development and management, personalized marketing strategies, and brand licensing. It also provides technical support and maintenance for distributors, along with health consulting (excluding diagnosis and treatment), network security software development, and big data services. Through these integrated offerings, the group enhances the market presence and operational efficiency of the ‘Dao Ling Doctor’ brand.”

Antiaging Quantum Living Inc. and its subsidiaries are collectively referred to as the “Company”.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), and include the assets, liabilities, revenues, expenses and cash flows of all subsidiaries. All significant inter-company transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.

In the opinion of management, the unaudited interim condensed financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. However, the results of operations included in such financial statements may not necessary be indicative of annual results.

The Company uses the same accounting policies in preparing quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2025 filed with the Securities and Exchange Commission (“SEC”) on July 2, 2025.

Use of Estimates

The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (the “SEC”).

The preparation of the Company’s financial statements in conformity with GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the financial statements and footnotes thereto. Actual results may differ from those estimates and assumptions.

Functional and presentation currency

The functional currency of the Company is the currency of the primary economic environment in which the Company operates which is Chinese Yuan (“RMB”). The RMB is not freely convertible into the US dollar and may be subject to PRC currency restrictions for payments, including the distributions of dividends or retained earnings to the Company by its subsidiaries or its variable interest entities.

Transactions in currencies other than the entity’s functional currency are recorded at the rates of exchange prevailing on the date of the transaction. At the end of each reporting period, monetary items denominated in foreign currencies are translated at the rates prevailing at the end of the reporting periods. Exchange differences arising on the settlement of monetary items and on translation of monetary items at period-end are included in income statement of the period.

For the purpose of presenting these financial statements, the Company’s assets and liabilities are expressed in US$ at the exchange rate on the balance sheet date, stockholder’s equity accounts are translated at historical rates, and income and expense items are translated at the weighted average exchange rate during the period. The resulting translation adjustments are reported under accumulated other comprehensive income (loss) in the stockholder’s equity (deficits) section of the balance sheets.

Exchange rate used for the translation as follows:

SCHEDULE OF EXCHANGE RATE

US$ to RMB	Period End		Average
September 30, 2025		7.1190		7.1947
March 31, 2025		7.2567		7.2163
September 30, 2024		7.0181		7.2015

Cash and Cash Equivalents

Cash and cash equivalents include cash in banks, bank deposits, and highly liquid investments with maturities of three months or less at the date of origination.

Accounts receivable, net

The Company records accounts receivable at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. The Company determines the allowance based on aging data, historical collection experience, customer specific facts and economic conditions. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote.

Advances to Suppliers

The Company occasionally makes advance payments to suppliers, contractors, and service providers to secure future deliveries of goods or completion of services. These advances are recorded as assets on the balance sheet and are reclassified to the appropriate expense or asset account (such as inventory, property and equipment, or repairs and maintenance) when the related goods are received or the services are rendered. These advances may include, but are not limited to, payments for inventory goods to be sold, deposits for services, or prepayments for capital improvements.

The Company periodically reviews the recoverability of advances to suppliers and establishes allowances for potential losses when necessary.

Other receivables and current assets

Other receivables and current assets consist primarily of prepaid expenses, advances, and refundable security deposits. These items are recorded at their original transaction amounts and are not discounted as the impact of discounting is not material to the consolidated financial statements. The Company evaluates the collectability of other receivables on a regular basis and establishes allowances for estimated credit losses, if necessary, in accordance with ASC 326.

Impairment of Other Assets

The Company has adopted Accounting Standards Codification subtopic 340-10, Other Assets (“ASC 340-10”). ASC 340-10 requires that prepaid expenses, deferred costs, and other capitalized expenditures be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates these assets for impairment periodically, or more frequently if events and circumstances warrant. Indicators of impairment may include contract cancellations, supplier bankruptcy, significant adverse changes in expected future benefits, or other factors reducing the asset’s recoverability.

The Company assesses recoverability based on the expected future benefits associated with the asset. If it is determined that the carrying value is no longer recoverable, the asset is written down to its net realizable value or zero if no recovery is expected. Impairment losses, if any, are recorded in the income statement as a charge to expense.

There were no write-offs on advances to suppliers for the six months ended September 30, 2025 and 2024, respectively.

Property and Equipment

Property and equipment are carried at cost net of accumulated depreciation. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset.

Property and equipment are depreciated on a straight-line basis over the following periods:

Leasehold improvements			2 years
Office furniture and equipment			3 years

Intangible assets

Intangible assets are carried at cost, net of accumulated amortization. Expenditures that enhance the functionality or extend the useful life of the intangible asset are capitalized. When intangible assets are retired or otherwise disposed of, the related gain or loss is included in operating income.

Intangible assets with finite useful lives are amortized on a straight-line basis over their estimated useful lives. The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.

Intangible assets are amortized on a straight-line basis over the following periods:

Patent

10 years

Impairment of Long-Lived Assets

The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (“ASC 360-10”). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve breakeven operating results over an extended period. The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.

Impairment loss on property and equipment were $3,955 and $nil for the six months ended September 30, 2025 and 2024, respectively.

Customer Advances

The Company records customer advances as liabilities when consideration is received in advance of the transfer of goods. These advances are recognized as revenue when the performance obligations associated with the advance are satisfied. These advances relate to the advance payment for orders of goods placed by the customers.

Leases

The Company adopted FASB Accounting Standards Codification, Topic 842, Leases (“ASC 842”) using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.

The new leasing standard requires recognition of leases on the balance sheets as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company’s future minimum based payments used to determine the Company’s lease liabilities mainly include minimum based rent payments. As most of the Company’s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The Company does not recognize any leases with an initial term of 12 months or less on the balance sheets.

Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.

Revenue Recognition

Revenue is recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. The Company determines revenue recognition by applying the following steps: 1) identification of the contract, or contracts, with a customer; 2) identification of the performance obligations in the contract; 3) determination of the transaction price; 4) allocation of the transaction price to the performance obligations in the contract; and 5) recognition of revenue when, or as, we satisfy a performance obligation.

Online advertising

The Company operates an online advertising platform that connects advertisers with publishers to display digital advertisements.

For the Company, revenue recognition occurs upon the following events: when a customer places an order, payment is received, and the advertisement is delivered and viewable to the end-user with no other terms and conditions.

Sales of goods

The Company operates a mobile application (“App”) through which it sells health and beauty products to customers.

For the Company, revenue recognition occurs upon the following events: when a customer places an order, payment is received, and the goods are delivered to or drop-shipped to and accepted by the customer. Provisions are made for estimated sales returns based on historical return rates and experience which are immaterial. The Company may record contract liabilities, such as customer advances, when payments are received from customers prior to delivery or acceptance of goods by customers.

Online platform technical operation support and maintenance services

The Company provides technical operation support and maintenance services for its online platforms, ensuring platform functionality, continuous availability, and technical support for end-users.

Revenue from these services is recognized ratably over each service period as the services are rendered, or upon completion of the service, depending on the nature of the arrangement. Billing frequency may vary (e.g., weekly, monthly, quarterly, or upon completion) as specified in the respective contracts. Service fees are determined based on contract terms and may be structured as fixed fees, milestone-based pricing, or as a percentage of gross transaction value (GTV) generated from the customer’s e-commerce platform. Each billing period or completed service cycle represents a distinct performance obligation, with revenue recognized upon completion and invoicing.

The major direct cost of providing these services is wages and salaries.

In instances where payments are received in advance, they are recorded as contract liabilities (deferred revenue) until the services are delivered.

For each revenue stream, the Company is a principal because it controls the specified goods or services before they are transferred to the customer. As a principal, the Company is primarily responsible for fulfilling the contractual obligations, has discretion in establishing the price, and bears the risk of inventory or service provision until completion, therefore revenue is recognized on a gross basis for each revenue stream.

Selling, General and Administrative Expenses

Selling, general, and administrative expenses primarily consist of costs related to sales and marketing activities, administrative functions, and certain start-up costs.

Selling expenses include, but are not limited to, sales commissions, advertising costs, shipping and handling expenses, and costs associated with trade shows and promotional events. General and administrative expenses encompass salaries and benefits of employees not directly involved in production, rent, utilities, office supplies, legal and professional fees, other overhead costs, and certain start-up costs.

Start-up costs represent expenses associated with the establishment of new operations, including activities such as market research, product development, and initial marketing efforts.

The Company recognizes these expenses as incurred, consistently matching with the revenues generated.

Defined Contribution Plans

The Company contributes to various government-mandated employee benefit plans in the People’s Republic of China, including pension, medical, unemployment, and housing provident funds. These contributions are made in accordance with local laws and regulations and are expensed as incurred. The Company’s obligations under these plans are limited to the amounts required to be contributed. For the six months ended September 30, 2025 and 2024, the Company contributed approximately $33,790 and $61,041, respectively.

Income Taxes

The Company records income tax expense using the asset-and-liability method of accounting for deferred income taxes. Under this method, deferred taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Deferred tax assets are reduced by a valuation allowance if, based on available evidence, it is more likely than not that the deferred tax assets will not be realized.

When tax returns are filed, it is likely some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. The benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more-likely-than-not the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount described above is reflected as a liability for unrecognized tax benefits in the accompanying balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest associated with unrecognized tax benefits is classified as interest expense and penalties are classified in general and administrative expenses in the statements of operations.

Earnings Per Share

The Company computes basic and diluted earnings per share amounts in accordance with ASC Topic 260, Earnings per Share. Basic earnings per share is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock that could share in the earnings of the Company.

As of September 30, 2025 and March 31, 2025, the Company does not have any potentially dilutive instrument.

Contingencies

Certain conditions may exist as of the date the financial statements are issued, which could result in a loss to the Company which will be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, and such assessment inherently involves judgment. In assessing loss contingencies arising from legal proceedings pending against the Company or unasserted claims that may rise from such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

If the assessment of a contingency indicates it is probable a material loss will be incurred and the amount of the loss can be reasonably estimated, then the estimated loss is accrued in the Company’s financial statements. If the assessment indicates a material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed.

Fair Value Measurements

Fair value accounting establishes a framework for measuring fair value and expands disclosure about fair value measurements. Fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. This framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows:

	●	Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liabilities, either directly or indirectly, for substantially the full term of the financial instruments.

	●	Level 3 inputs to the valuation methodology are unobservable and significant to the fair value.

The Company’s financial instruments consisted of cash, accounts receivables, accounts payable, contract liabilities and loan from shareholders. The estimated fair value of those balances approximates the carrying amount due to the short maturity of these instruments.

Credit Losses on Financial Instruments

The Company recognizes credit losses on financial instruments in accordance with Accounting Standards Codification (ASC) Topic 326, Financial Instruments – Credit Losses. The Company uses the Current Expected Credit Losses (CECL) model to estimate credit losses on financial assets measured at amortized cost, as well as certain off-balance sheet credit exposures.

Under the CECL model, the estimation of credit losses involves significant judgment and estimation uncertainty. Management exercises its judgment based on historical loss experience, current economic conditions, and reasonable and supportable forecasts. Changes in these factors could have a material impact on the estimated credit losses.

Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker (the “CODM”), which is comprised of the chief executive officer of the Company’s management team. Consequently, the Company has determined that it has only one reportable operating segment.

Recent Accounting Pronouncements

Accounting Standards Update (“ASU”) 2025-06, Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software modernizes the accounting for internal-use software by removing the requirement to identify discrete project development stages (such as the preliminary and application-development stages) and instead focuses on whether (1) management has authorized and committed to funding the project, (2) it is probable the project will be completed and the software will be used to perform its intended function, and (3) the entity has considered whether significant uncertainty exists in the development activities. The amendments are effective for fiscal years beginning after December 15, 2027, and for interim periods within those fiscal years. Early adoption is permitted. Entities may apply the amendments prospectively, retrospectively, or using a modified-prospective approach. The Company is currently evaluating the impact of ASU 2025-06 on its consolidated financial statements and related disclosures. The adoption is expected to primarily affect the timing of capitalizing certain software-development costs and may result in modifications to internal controls over capitalization judgments and related disclosures.

ASU 2025-05, Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets introduces a practical expedient for measuring expected credit losses on current accounts receivable and current contract assets arising from contracts with customers under Topic 606. Under the expedient, entities may assume that conditions existing at the balance sheet date will remain unchanged over the asset’s remaining life when estimating expected credit losses. In addition, entities other than public business entities may elect, as an accounting policy, to consider subsequent cash collections that occur after the balance sheet date but before issuance of the financial statements when estimating expected credit losses. The amendments are effective for fiscal years beginning after December 15, 2025, and for interim periods within those fiscal years. Early adoption is permitted, and the guidance is to be applied prospectively. The Company is currently evaluating the impact of ASU 2025-05 and does not expect the adoption to have a material impact on its consolidated financial statements. The Company expects to apply the practical expedient for qualifying current receivables and contract assets upon adoption.

ASU 2025-04, Compensation—Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Customer Share-Based Payment Awards, clarifies how entities account for share-based consideration payable to a customer. The ASU requires customer awards with vesting conditions tied to purchases to be treated as performance conditions, eliminates the forfeiture policy election, and states that the variable consideration constraint under ASC 606 does not apply to these awards. The standard is effective for annual periods beginning after December 15, 2026, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its financial statements.

ASU 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Accounting Acquirer in a Business Combination Involving a Variable Interest Entity, clarifies that when a business that is a VIE is acquired primarily with equity interests, the determination of the accounting acquirer should follow ASC 805 rather than defaulting to the primary beneficiary under ASC 810. The standard is effective for fiscal years beginning after December 15, 2026, including interim periods within those fiscal years. Early adoption is permitted. The Company does not expect a material impact upon adoption.

ASU 2025-02, Liabilities (Topic 405): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 122, removes the guidance previously provided under SAB 121 and codified in ASC 405-S99. The amendment reflects the SEC’s rescission of SAB 121 and clarifies that custodians of crypto-assets should assess loss contingencies under ASC 450-20. This update is effective retrospectively for public business entities for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this standard to have a material impact on its financial statements.

ASU 2025-01, Presentation of Financial Statements (Topic 220): Clarifying the Effective Date of Disaggregation of Income Statement Expenses, confirms the effective date of ASU 2024-03 for public business entities. The guidance requires disaggregated expense information in the income statement and is effective for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after that date. Early adoption is permitted. The Company is currently evaluating the impact of this standard.

ASU 2024-03, “Debt—Debt with Conversion and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments”. The amendments in this ASU are effective for fiscal years beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted as of the beginning of a reporting period if the entity has also adopted ASU 2020-06 for that period. The Company is evaluating the impact of the standard on its consolidated financial statements and disclosures.

ASU 2024-03, Disaggregation of Income Statement Expenses. The guidance primarily will require enhanced disclosures about certain types of expenses. The amendments in ASU 2024-03 are effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027 and may be applied either on a prospective or retrospective basis. The Company is evaluating the impact of the standard on its consolidated financial statements and disclosures.

Management does not believe that other recently issued but not yet adopted accounting pronouncements will have a material impact on the Company’s financial position, results of operations, or cash flows.

NOTE 3 – GOING CONCERN

The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities and commitments in the normal course of business. The Company has incurred net loss of $194,970 for the period ended September 30, 2025, had an accumulated deficit of $1,604,682, and working capital of $23,279 . These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern.

Management’s plan to alleviate the substantial doubt about the Company’s ability to continue as a going concern include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations to meet its operating needs on a timely basis, obtain additional working capital funds from the majority shareholder and President of the Company to eliminate inefficiencies in order to meet its anticipated cash requirements. However, there can be no assurance that these plans and arrangements will be sufficient to fund the Company’s ongoing capital expenditures and other requirements.

The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

NOTE 4 – ACCOUNTS RECEIVABLES

Accounts receivables, net comprised of the following:

SCHEDULE OF ACCOUNTS RECEIVABLES

	September 30, 2025		March 31, 2025
Accounts receivables	$	467,804	$	85,788
Less: Allowance for credit loss		-		-
Total, net	$	467,804	$	85,788

There was no allowance for credit loss expenses for the six months ended September 30, 2025 and 2024, respectively.

NOTE 5 – OTHER RECEIVABLES AND CURRENT ASSETS

Other receivables and current assets, net comprised of the following:

	September 30, 2025		March 31, 2025
Other receivables and prepayments	$	155,612	$	165,740
Security deposits		56,939		56,315
Less: Allowance for credit loss		-		-
Total, net	$	212,551	$	222,055

There was no allowance for credit loss expenses for the six months ended September 30, 2025 and 2024, respectively.

NOTE 6 – PROPERTY AND EQUIPMENT

Property and equipment, net comprised of the following:

SCHEDULE OF PROPERTY AND EQUIPMENT

	September 30, 2025			March 31, 2025
At Cost:
Leasehold improvements	$	367,473		$	248,614
Office furniture and equipment		70,101			22,716
Property plant and equipment , gross		70,101			22,716
Total cost		437,574			271,330
Less: Accumulated depreciation		(233,197	)		(150,561	)
Total, net	$	204,377		$	120,769

Depreciation expenses were $79,089 and $71,921 for the six months ended September 30, 2025 and 2024, respectively.

Impairment losses were $3,955 and $nil for the six months ended September 30, 2025 and 2024, respectively.

The Company did not dispose of any fixed assets for the six months ended September 30, 2025 and 2024, respectively. Accordingly, no gain or loss on disposal of fixed assets was recognized.

NOTE 7 – INTANGIBLE ASSET

Intangible asset, net comprised of the following:

SCHEDULE OF INTANGIBLE ASSET

	September 30, 2025			March 31, 2025
At Cost:
Patent	$	14,046		$	13,781
Total cost		14,046			13,781
Less: Accumulated amortization		(936	)		(230	)
Total, net	$	13,110		$	13,551

Amortization expenses were $695 and $nil for the six months ended September 30, 2025 and 2024, respectively.

The amortization expenses for the succeeding five years as follows:

For the year ending March 31,
2026 (6 months remaining)	$	702
2027		1,405
2028		1,405
2029		1,405
2030		1,405
Total	$	6,322

NOTE 8 – LOANS PAYABLE AND NOTES PAYABLE

On December 31, 2024, the Company entered into a promissory note agreement amending the terms of existing loan agreements with outstanding balances of CNY 3,931,167 (approximately $538,568). and CNY 2,096,172 (approximately $287,174), including an extension of the maturity date to December 31, 2029. As a result, the outstanding balances are classified as “Notes Payable”. These notes are unsecured, non-interest-bearing, and with a maturity date of December 31, 2029. In prior periods, these balances are presented as “Loan Payables” consistent with the classification applicable at that time.

On March 24, 2025, the Company borrowed CNY 2,800,000 ($386,042) from the unrelated third party pursuant to a loan agreement. The loan is unsecured, non-interest-bearing, with a maturity date of December 9, 2027.

On March 31, 2025, the Company entered into a Tripartite Debt Assignment Agreement with Mr. Barry Wan (a related party) and the unrelated party, pursuant to which the CNY 2,096,172 ($288,860) note, the CNY 2,800,000 ($385,850) loan, and the CNY 3,931,167 ($541,730) note; were legally assigned to Mr. Wan. Following the assignment, Mr. Wan became the holder of the obligations under the same terms and conditions. (Refer to Note 9 for details)

As of September 30, 2025 and March 31, 2025, there was no outstanding balance of the Notes Payable and loans payable to unrelated third party.

NOTE 9 – RELATED PARTY TRANSACTIONS

Due to related parties

Due to related parties comprised of the following:

SCHEDULE OF DUE TO RELATED PARTIES

September 30,

2025

March 31,
2025

Barry Wan (“Mr. Wan”)

860,000

520,000

Total

860,000

520,000

Due to related parties balances above are unsecured and non-interest-bearing.

Promissory notes payable and loans payable

Promissory notes payable and loans payable related parties comprised of the following:

	September 30, 2025		March 31, 2025
Mr. Wan – Promissory note maturity date December 31, 2029	$	1,275,445	$	1,259,380
Mr. Wan – Loans maturity date December 9, 2027		393,314		385,850
Loans payable		393,314		385,850
New Lite – Promissory note maturity date December 31, 2029		29,571		29,571
Promissory note payable		29,571		29,571
Total	$	1,698,330	$	1,674,801
Total promissory notes payable and loans payable	$	1,698,330	$	1,674,801

All promissory notes and loans payable are unsecured and non-interest-bearing.

Advances from Mr. Wan

During the six months ended September 30, 2025, the Company received advances from Mr. Wan, our President for working capital purpose. The outstanding amount due to Mr. Wan was $860,000 and $520,000 as of September 30, 2025 and March 31, 2025, respectively. The advance is unsecured, non-interest-bearing and due on demand. On December 31, 2024, the Company formalized a promissory note agreement for $428,790 with a maturity date of December 31, 2029.

Debt Assignment to Mr. Wan

On March 31, 2025, the Company entered into a Tripartite Debt Assignment Agreement with Mr. Barry Wan (a related party) and the unrelated third-party original lender, pursuant to which the CNY 2,096,172 ($288,860) note, the CNY 2,800,000 ($385,850) loan, and the CNY 3,931,167 ($541,730) note; were legally assigned to Mr. Wan. Following the assignment, Mr. Wan became the holder of the obligations under the same terms and conditions.

Advances from Tairan Baohe Insurance Sales Co., Ltd. (“Tairan”)

During the year ended March 31, 2025, the Company borrowed funds from Tairan, an entity where Mr. Wan’s spouse is a shareholder, for working capital purpose. The outstanding amount due to Tairan was $nil and $nil as of September 30, 2025 and March 31, 2025, respectively. The loan was unsecured, non-interest-bearing and due on demand. On December 31, 2024, the Company formalized a promissory note agreement for CNY 2,800,000 (approximately $383,598) with a maturity date of December 31, 2029. Subsequently, on March 24, 2025, the Company repaid the full outstanding balance to Tairan. As a result, the amount due to Tairan was $nil as of September 30, 2025.

Advances from New Lite Ventures LLC (“New Lite”)

During the year ended March 31, 2025, the Company borrowed funds from New Lite, an entity where Mr. Wan is a controlling member, for working capital purpose. The amount was unsecured, non-interest-bearing and due on demand.

On December 31, 2024, the Company formalized a promissory note agreement for $29,571 with a maturity date of December 31, 2029.

NOTE 10 – INCOME TAX

The Company has not recognized an income tax benefit for its operating losses generated based on uncertainties concerning its ability to generate taxable income in future periods. The tax benefit for the period presented is offset by a valuation allowance established against deferred tax assets arising from the net operating losses, the realization of which could not be considered more likely than not. In future periods, tax benefits and related deferred tax assets will be recognized when management considers realization of such amounts to be more likely than not.

United States

Net operation losses (“NOLs”) can carry forward indefinitely up to offset 80% of taxable income after CARES Act effect on December 31, 2017. As of September 30, 2025, deferred tax assets resulted from NOLs of approximately $250,000, respectively. The deferred tax asset has been fully reserved by a valuation allowance as the Company believes they will most-likely-than-not realize the benefits.

Hong Kong

Companies incorporated in Hong Kong are subject to Hong Kong Profits Tax on the taxable income as reported in its statutory financial statements adjusted in accordance with relevant Hong Kong tax laws. The applicable tax rate is 16.5% on its taxable income generated from operations in Hong Kong. The Company did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earned in Hong Kong since inception. Additionally, payments of dividends by the subsidiary incorporated in Hong Kong to the Company are not subject to any Hong Kong withholding tax.

PRC

Effective on January 1, 2008, the PRC Enterprise Income Tax Law, EIT Law, and Implementing Rules impose a unified enterprise income tax rate of 25% on all domestic-invested enterprises and foreign investment enterprises in PRC, unless they qualify under certain limited exceptions. As such, starting from January 1, 2008, the Company’s subsidiaries in PRC are subject to an enterprise income tax rate of 25%. NOLs can typically carried forward for a certain number of years (usually five years) to offset against future taxable income. As of September 30, 2025, the Company’s PRC operations had net operating losses which resulted in deferred tax assets of approximately $226,000. The deferred tax asset has been fully reserved for valuation allowance as the Company believes they will most-likely-than-not realize the benefits.

Income Taxes Paid

For the six months ended September 30, 2025, the Company paid income taxes of $10,388 in China , and did not pay any income taxes domestically or in foreign jurisdictions for the six months ended September 30, 2024.

The following table summarizes the taxable income (loss) before income taxes by jurisdiction:


	Six months ended September 30,
	2025			2024
United States	$	(405,811	)	$	(70,281	)
Hong Kong		-			-
China		227,286			(341,373	)
Total	$	(178,525	)	$	(411,654	)

The following table summarizes a reconciliation of income tax expense for operations, calculated at the statutory income tax rate to total income tax expense (benefit):


	Six months ended September 30,
	2025			2024
Loss before income taxes	$	(178,525	)	$	(411,654	)
U.S. federal tax benefits (21%)		(85,220	)		(14,759	)
State tax benefit, net of federal benefits		(30,436	)		(5,271	)
PRC tax expenses (benefits) (25%)		56,821			(85,343	)
Hong Kong tax benefits (16.5%)		-			-
Income tax benefits at statutory rate		(58,835	)		(105,373	)
Foreign tax rate differential		-			-
Change in valuation allowance		75,280			105,373
Other		-			-
Provision for income taxes expenses	$	16,445		$	-
Effective tax rate		(13.21	)%		0	%

NOTE 11 – SHAREHOLDERS’ EQUITY

The Company is authorized to issued 1,200,000,000 shares of Class A common stock, 1,200,000,000 Class B common stock, 1,200,000,000 Class C common stock, 1,200,000,000 Class D common stock, and 1,200,000,000 Class E common stock; all with a par value of $0.00001 per share.

As of September 30, 2025, the Company had 29,995,000 shares of Class A common stock issued and outstanding; and no shares of Class B, Class C, Class D, or Class E common stock were issued and outstanding.

On March 28, 2023, the Company amended its article with New York State to change the authorized common shares with a par value of $0.001 to 30,000,000 shares, no preferred shares.

During the years ended March 31, 2024, a shareholder loan in the amount of $83,300 was forgiven by our former President and recorded as additional paid-in capital.

On June 6, 2024, the Company amended its article with New York State to increase the authorized shares of common stock of the Company from thirty million (30,000,000) shares of common stock, par value $0.001 per share, to six billion (6,000,000,000) shares of common stock, par value $0.00001 per share (the “Authorized Capital Increase”). Upon the effectiveness of the authorized shares increase, the shares of common stock will be categorized as follows: 1,200,000,000 Class A shares, 1,200,000,000 Class B shares, 1,200,000,000 Class C shares, 1,200,000,000 Class D shares, and 1,200,000,000 Class E shares.

NOTE 12 – DISAGGREGATION OF REVENUE

The Company disaggregates its revenue by major revenue streams, as the Company believes this disaggregation best depicts how the nature, amount, timing and uncertainty of the revenue and cash flows are affected by economic factors.
SCHEDULE OF DISAGGREGATION OF REVENUE


	Six months ended September 30,
	2025		2024
Sales of goods (Health and beauty products)	$	-	$	123,736
Technical operation support and maintenance services		681,602		251,507
Total	$	681,602	$	375,243

NOTE 13 – LEASES

The Company has various operating leases for its office space and retail space.

Operating lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate the present value is incremental borrowing rate or, if available, the rate implicit in the lease. The Company determines the incremental borrowing rate for each leases based primarily on its lease term.

Certain lease agreements may include renewal options that are exercisable at the Company’s discretion. The Company includes renewal periods in the lease term when it is reasonably certain that the renewal option will be exercised. For leases where the renewal is not reasonably certain, the extension options are excluded from the measurement of lease liabilities and right-of-use assets. The lease term used reflects only the non-cancellable period and any renewal options that the Company is reasonably certain to exercise.

Operating lease expenses were $197,511 and $150,385 for the six months ended September 30, 2025 and 2024, respectively. The Company did not have short-term leases or subleases for the six months ended September 30, 2025 and 2024. Lease payments are fixed and increase annually according to the stated terms in the lease agreements. The Company does not have any variable lease payments.

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

	Six months ended September 30,
	2025			2024
Lease cost
Operating lease cost	$	197,511		$	150,385

Other Information
Cash paid for amounts included in the measurement of lease liabilities	$	36,000		$	-
Weighted average remaining lease term – operating leases (in years)		2.19			1.25
Average discount rate – operating lease		4.75	%		4.75	%

The supplemental balance sheet information related to leases is as follows:

	September 30, 2025		March 31, 2025
Operating leases
Right-of-use assets	$	463,787	$	644,515
Operating lease liabilities	$	390,709	$	412,790

The undiscounted future minimum lease payment schedule as follows:

For the year ending March 31,
2026 (6 months remaining)	$	37,080
2027		75,272
2028		77,531
2029		79,856
2030		82,252
Thereafter		127,706
Total undiscounted lease payments		479,697
Less: interest		(88,988	)
Total lease liabilities	$	390,709

NOTE 14 – RISKS, COMMITMENTS AND CONTINGENCIES

Litigations and claims

To the best of the Company’s knowledge and based on information available as of September 30, 2025, the Company is not involved in any material claims or legal actions arising from the ordinary course of business. However, the Company is exposed to various risks and uncertainties that could potentially result in litigation or claims in the future. The Company continuously evaluates these contingencies and will adjust its disclosures as necessary.

Concentration Risks

For the six months ended September 30, 2025, 100% of the Company’s revenue was derived from a single customer. As of September 30, 2025, 100% of the Company’s accounts receivable balance was due from this customer.

The Company is economically dependent on this customer, and the loss of this relationship could have a material adverse effect on its financial condition, results of operations, and cash flows.

NOTE 15 – SUBSEQUENT EVENTS

The Company evaluated all events or transactions that occurred after September 30, 2025 through the date the financial statements were issued. During the period, the Company did not have any material recognizable subsequent events required to be disclosed or adjusted as of and for the six months ended September 30, 2025.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains forward-looking statements, particularly those identified with the words, “anticipates,” “believes,” “expects,” “plans,” “intends,” “objectives,” and similar expressions. These statements reflect management’s best judgment based on factors known at the time of such statements. The reader may find discussions containing such forward-looking statements in the material set forth under “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” generally, and specifically therein under the captions “Liquidity and Capital Resources” as well as elsewhere in this Quarterly Report on Form 10-Q. Actual events or results may differ materially from those discussed herein. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict and no representation, guarantee, or warranty is to be inferred from those forward-looking statements. The assumptions used for purposes of the forward-looking statements specified in the following information represent estimates of future events and are subject to uncertainty as to possible changes in economic, legislative, industry, and other circumstances. As a result, the identification and interpretation of data and other information and their use in developing and selecting assumptions from and among reasonable alternatives require the exercise of judgment. To the extent that the assumed events do not occur, the outcome may vary substantially from anticipated or projected results, and, accordingly, no opinion is expressed on the achievability of those forward-looking statements. No assurance can be given that any of the assumptions relating to the forward-looking statements specified in the following information are accurate, and we assume no obligation to update any such forward-looking statements.

Overview

Antiaging Quantum Living Inc. (FKA: Achison Inc.) (the “Company”, “us”, “we” or “our”) was incorporated under the laws of the State of New York on December 29, 2014.

On July 1, 2019, Lansdale Inc., the principal stockholder of the Company (“Seller”) and an entity controlled by the Company’s former President, Mr. Wanjun Xie, entered into a Stock Purchase Agreement (the “Agreement”) with Dazhong 368 Inc., (the “Buyer”), pursuant to which, a total of 9,000,000 shares of Class A common stock of the Company were transferred to the Buyer, representing approximately 90% of the Company’s issued and outstanding shares of Class A common stock, resulting in a change of the control of the Company. Mr. Dingshan Zhang was appointed as the President and CEO of the Company on the same date.

On April 10, 2023, Mr. Barry Wan acquired control of 29,215,000 restricted shares of Class A common stock (the “Purchased Shares”) of the Company, representing approximately 97% of the Company’s total issued and outstanding common stock from Dazhong 368 Inc and Sophia 33 Inc, two New York corporations controlled by the Company’s then President, Chief Executive Officer and sole director, Dingshan Zhang (the former President) pursuant to the terms of a Stock Purchase Agreement by and among the parties thereto (the “Stock Purchase Agreement”). Pursuant to the Stock Purchase Agreement, Mr. Wan paid an aggregate purchase price of four hundred thousand dollars ($400,000.00) to Mr. Zhang in exchange for the purchased shares. The foregoing transaction resulted in a change of control of the Company, with Mr. Wan acquiring 97% of the Company’s outstanding Class A common stock held through New Lite Ventures LLC, a New York LLC. Both before and after the transactions, the Company had 29,995,000 shares of its Class A common stock outstanding.

In connection with the transaction, on April 10, 2023, Mr. Dingshan Zhang resigned from all positions he held with the Company. On April 10, 2023, Ms. Jing Wan was appointed by our majority shareholder as our Chief Executive Officer, Chief Financial Officer, President and Director. On June 16, 2023, Mr. Barry Wan consented to act as the new Chief Executive Officer and Chief Financial Officer after Ms. Jing Wan resigned. The Company changed its name to Antiaging Quantum Living Inc. on June 14, 2023.

The change in control with respect to the Company was effectuated to better reflect its new business direction, with the intention of acquiring businesses involved in healthcare management and insurance services.

In line with this expansion, the Company established AAQL Inc. AAQL HK Limited Dao Ling Doctor Hangzhou, Dao Ling Doctor Zhejiang, and Dao Ling Doctor Huzhou entities.

On July 25, 2024, the Board of Directors of the Company approved the appointment of J&S Associate PLT to be the new independent registered public accounting firm for the financial period ending June 30, 2024. This appointment addressed the vacancy created by the resignation of PWN LLP as the Company’s former independent registered public accounting firm.

On September 6, 2024, the holders of a majority of the issued and outstanding voting securities of the Company approved an amendment to its Certificate of Incorporation increase in the number of authorized shares of common stock of the Company from thirty million (30,000,000) shares of common stock, par value $0.001 per share, to six billion (6,000,000,000) shares of common stock, par value $0.00001 per share (the “Authorized Capital Increase”). Upon the effectiveness of the Authorized Capital Increase, the shares of common stock will be categorized as follows: 1,200,000,000 Class A shares, 1,200,000,000 Class B shares, 1,200,000,000 Class C shares, 1,200,000,000 Class D shares, and 1,200,000,000 Class E shares. On the same day, the Certificate of Amendment to the Certificate of Incorporation of the Company was filed with New York State Department effectuating the Authorized Capital Increase.

Results of Operation for the three months ended September 30, 2025 and 2024

	2025			2024			$ Changed		% Changed
Revenue		390,164			173,174			216,990		125.30	%
Cost of revenues		65,691			14,373			51,318		357.04	%
Gross profit		324,473			158,801			165,672		104.33	%
Gross margin		83.16	%		91.70	%				-8.54	%
Selling, general and administrative expenses		375,695			356,569			19,126		5.36	%
Loss from operations		(51,222	)		(197,768	)		146,546		-74.10	%
Other income		69			22			47		213.64	%
Income tax expenses		10,445			0			10,445		100.00	%
Net loss		(61,598	)		(197,746	)		136,148		-68.85	%

During the three months ended September 30, 2025 and 2024, the Company generated revenues of $390,164 and $173,174, respectively. The increase in revenue was primarily due to continued growth of the Company’s online platform technical operation support and maintenance services for the period which commenced in 2024. In addition, the Company’s subsidiary Anti-Aging Care LLC began limited operations during the three months ended September 30, 2025 which contributed to the overall increase in revenues for the current period.

Cost of revenues was $65,691 and $14,373 for the three months ended September 30, 2025 and 2024, respectively. Gross profit increased to $324,473 (gross margin of 83.16%) for the three months ended September 30, 2025, as compared to gross profit of $158,801 (gross margin of 91.70%) for the three months ended September 30, 2024. The change in gross margin is primarily due to the shift in revenue streams to technical support and maintenance services business, which carries a different cost structure.

The Company incurred operating expenses of $375,695 and $356,569 for the three months ended September 30, 2025 and 2024, respectively. The increase in operating expenses was mainly due to the increase rental and facility costs.

For the three months ended September 30, 2025 and 2024, the Company’s other income was $69 and $22, respectively, which consisted of interest income.

For the three months ended September 30, 2025, our net loss was $61,598 comparing to a net loss of $197,746 for the three months ended September 30, 2024. The decrease in net loss is mainly due to the increased revenues.

Results of Operation for the six months ended September 30, 2025 and 2024

	2025			2024			$ Changed			% Changed
Revenue		681,602			375,243			306,359			81.64	%
Cost of revenues		122,397			14,538			107,859			741.91	%
Gross profit		559,205			360,705			198,500			55.03	%
Gross margin		82.04	%		96.13	%					-14.08	%
Selling, general and administrative expenses		748,630			772,406			(23,776	)		-3.08	%
Loss from operations		(189,425	)		(411,701	)		222,276			-53.99	%
Other income		10,900			47			10,853			23091.49	%
Income tax expenses		16,445			0			16,445			100.00	%
Net loss		(194,970	)		(411,654	)		216,684			-52.64	%

During the six months ended September 30, 2025 and 2024, the Company generated revenues of $681,602 and $375,243, respectively. The increase in revenue was primarily due to continued growth of the Company’s online platform technical operation support and maintenance services for the period, which commenced in 2024. which accounted for the entire revenue for the current period. In addition, the Company’s subsidiary Anti-Aging Care LLC began limited operations during the three months ended September 30, 2025 which contributed to the overall increase in revenues for the current period.

Cost of revenues was $122,397 and $14,538 for the six months ended September 30, 2025 and 2024, respectively. Gross profit increased to $559,205 (gross margin of 82.04%) for the six months ended September 30, 2025, as compared to gross profit of $360,705 (gross margin of 96.13%) for the six months ended September 30, 2024.

The change in gross margin is primarily due to the shift in revenue streams to technical support and maintenance services business, which carries a different cost structure.

The Company incurred operating expenses of $748,630 and $772,406 for the six months ended September 30, 2025 and 2024, respectively. The decrease in operating expenses was mainly due to the decrease in employee wages and benefits and legal and professional fees.

For the six months ended September 30, 2025, the Company received renovation subsidy of $10,810, which was recognized as other income, along with interest income.

For the six months ended September 30, 2025, our net loss was $194,970 comparing to a net loss of $411,654 for the six months ended September 30, 2024. The decrease in net loss is mainly due to the increased revenues and increase of other income.

Equity and Capital Resources

As of September 30, 2025, we had an accumulated deficit of $1,604,682 and working capital of $23,279 , compared to accumulated deficit of $1,409,712 and a working capital of $132,689 as of March 31, 2025.

The decrease in the working capital was primarily driven by the increases in accounts receivables offset by the increase in operating lease liabilities – current portion and due to related parties, which impacted available cash.

The Company’s net loss was partially offset by non-cash expenses, including $79,784 in depreciation and amortization, and $197,511 in amortization related to right-of-use (ROU) assets, mainly associated with leased office and retail spaces and leasehold improvements. Additionally, an increase of accounts receivables of $376,353 and an increase in inventories of $72,250 affected net cash used in operating activities for the six months ended September 30, 2025.

During the six months ended September 30, 2025 and 2024, the Company purchased fixed assets totaling $163,441 and $44,820, respectively.

During the six months ended September 30, 2025 and 2024, the Company received advances of $340,000 and $138,745 from related parties for working capital purposes, which shareholders are prepared to provide additional funding as needed.

As of September 30, 2025, we held approximately $455,446 in cash and cash equivalents. Our liabilities are primarily funded by shareholder loans and unrelated parties’ loans, which do not require immediate repayment. Operations are continuing as usual, and management is committed to implementing expense control measures in the near term to support liquidity.

Going Concern Assessment

The Company demonstrates adverse conditions that raise substantial doubt about the Company’s ability to continue as a going concern. These adverse conditions are negative financial trends, specifically cash outflow from operating activities, operating losses, accumulated deficit and other adverse key financial ratios.

Management’s plan to alleviate the substantial doubt about the Company’s ability to continue as a going concern include attempts to consummate a business combination and to generate sufficient cash flow from its operations to meet its operating needs on a timely basis; as well as to obtain additional working capital funds as loans from the majority shareholder and the President of the Company.

The unaudited condensed and consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that the Company cannot continue as a going concern.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Critical Accounting Policies

The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires making estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The critical accounting policies are discussed in further detail in the notes to the unaudited financial statements appearing elsewhere in this 10-Q report. Management believes that the application of these policies on a consistent basis enables us to provide useful and reliable financial information about our operating results and financial condition

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company” we are not required to provide this information under this item pursuant to Regulation S-K.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed with an objective of ensuring that information required to be disclosed in our periodic reports filed with the Securities and Exchange Commission, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission. Disclosure controls are also designed with an objective of ensuring that such information is accumulated and communicated to our management, including our chief executive officer, in order to allow timely consideration regarding required disclosures.

The evaluation of our disclosure controls by our principal executive officer included a review of the controls’ objectives and design, the operation of the controls, and the effect of the controls on the information presented in this Annual Report. Based on our management’s evaluation, our Chief Executive Officer, have concluded that as of such date, our disclosure controls were not, in design and operation, effective at a reasonable assurance level due to the material weaknesses in internal control over financial reporting. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Also, projections of any evaluation of the disclosure controls and procedures to future periods are subject to the risk that the disclosure controls and procedures may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that there were material weakness in our internal controls over Financial reporting as of June 30, 2025 and they were therefore not as effective as they could be to ensure that information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. The material weakness in our controls and procedure were lack of US GAAP knowledge and segregation duties. Management does not believe that any of these material weaknesses materially affected the results and accuracy of its financial statements. However, in view of this discovery of such weaknesses, management has begun a review to improve them.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 under the Exchange Act that occurred during the quarter ended September 30, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

None

Item 1A. Risk Factors.

As a “smaller reporting company”, we are not required to provide this information under this item pursuant to Regulation S-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit Number		Description of Exhibit

31.1**		Certification of Principal Executive Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2**		Certification of Principal Financial Officer pursuant to the Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act.

32.1**		Certification of Principal Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		Inline XBRL Instance Document

101.SCH		Inline XBRL Taxonomy Extension Schema Document

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

** Filed herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ANTIAGING QUANTUM LIVING INC

Date: November 12, 2025	/s/ Barry Wan
	Barry Wan, Chief Executive Officer

Date: November 12, 2025	/s/ Barry Wan
	Barry Wan, Chief Financial Officer

Antiaging Quantum Living Inc. 10-Q